指南与共识腹部技术与安全US

肝脏影像报告和数据系统对比增强超声非放射治疗反应评估2024版

Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024.
PubMed 文献 · Radiology · 2024-01-01

美国放射学会肝脏影像报告和数据系统(LI-RADS)新增对比增强超声(CEUS)非放射治疗反应评估(TRA)v2024,提供影像术语、技术及评估肿瘤活性的标准。该版区分病灶内与病灶周边增强采用不同诊断标准:病灶内增强标准较宽以提高敏感性,病灶周边增强标准较严以减少治疗后反应性改变误判为活性肿瘤,最终统一归入LR-TR无活性、不确定或活性三类。

要点

  • CEUS对血流高度敏感,治疗后反应性改变常表现为病灶周围异常增强且无廓清,尤其治疗后前3个月。
  • 病灶内增强采用较宽标准以提高肿瘤活性检出敏感性,病灶周边增强采用较严标准以降低反应性改变误判。
  • TRA算法综合病灶内与病灶周边活性评估,给出单一LR-TR类别:无活性、不确定或活性。

核心结论

  • LI-RADS CEUS非放射TRA v2024提供治疗后肿瘤活性评估的术语、技术和影像标准,通过区分病灶内与病灶周边增强采用不同诊断标准,提高CEUS评估准确性。

研究设计与样本

  • 美国放射学会LI-RADS发布的版本2024概述报告,涵盖CEUS非放射治疗反应评估的影像术语、技术及治疗后肿瘤活性评估的影像标准。

关键影像表现/征象

  • CEUS对血管血流高度敏感,治疗后反应性改变常表现为病灶周围异常增强且无廓清,尤其在治疗后前3个月。
  • 病灶内增强采用较宽标准以提高肿瘤活性检出敏感性。
  • 病灶周边增强采用较严标准以限制将治疗后反应性改变误分类为活性肿瘤。

诊断标准与关键数值

  • 病灶内增强采用较宽标准以提高肿瘤活性检出敏感性。
  • 病灶周边增强采用较严标准以限制将治疗后反应性改变误分类为活性肿瘤。
  • TRA算法综合病灶内与病灶周边肿瘤活性评估,分配单一LR-TR类别:LR-TR无活性、LR-TR不确定或LR-TR活性。

临床应用与阅片要点

  • CEUS非放射TRA v2024考虑活性肿瘤与治疗后改变在CEUS表现上的差异,包括病灶内及紧邻病灶区域。
  • 由于CEUS对血流高度敏感,治疗后反应性改变常表现为病灶周围异常增强且无廓清,尤其在治疗后前3个月,阅片时需注意与活性肿瘤鉴别。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

The American College of Radiology Liver Imaging Reporting and Data System (LI-RADS) standardizes the imaging technique, reporting lexicon, disease categorization, and management for patients with or at risk for hepatocellular carcinoma (HCC). LI-RADS encompasses HCC surveillance with US; HCC diagnosis with CT, MRI, or contrast-enhanced US (CEUS); and treatment response assessment (TRA) with CT or MRI. LI-RADS was recently expanded to include CEUS TRA after nonradiation locoregional therapy or surgical resection. This report provides an overview of LI-RADS CEUS Nonradiation TRA v2024, including a lexicon of imaging findings, techniques, and imaging criteria for posttreatment tumor viability assessment. LI-RADS CEUS Nonradiation TRA v2024 takes into consideration differences in the CEUS appearance of viable tumor and posttreatment changes within and in close proximity to a treated lesion. Due to the high sensitivity of CEUS to vascular flow, posttreatment reactive changes commonly manifest as areas of abnormal perilesional enhancement without washout, especially in the first 3 months after treatment. To improve the accuracy of CEUS for nonradiation TRA, different diagnostic criteria are used to evaluate tumor viability within and outside of the treated lesion margin. Broader criteria for intralesional enhancement increase sensitivity for tumor viability detection. Stricter criteria for perilesional enhancement limit miscategorization of posttreatment reactive changes as viable tumor. Finally, the TRA algorithm reconciles intralesional and perilesional tumor viability assessment and assigns a single LI-RADS treatment response (LR-TR) category: LR-TR nonviable, LR-TR equivocal, or LR-TR viable.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lyshchik A, Fetzer DT, Kono Y, et al. Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024. Radiology. 2024. PMID: 38805727. doi:10.1148/radiol.232369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。